Show simple item record

dc.contributor.authorGarrido, Victoria
dc.contributor.authorPiñero Lambea, Carlos
dc.contributor.authorRodriguez Arce, Irene
dc.contributor.authorPaetzold, Bernhard
dc.contributor.authorFerrar, Tony
dc.contributor.authorWeber, Marc
dc.contributor.authorGarcia-Ramallo Pla, EVA
dc.contributor.authorGallo, Carolina
dc.contributor.authorCollantes, María
dc.contributor.authorPeñuelas, Ivan
dc.contributor.authorSerrano, Luis
dc.contributor.authorGrillo, Maria-Jesus
dc.contributor.authorLluch, Maria
dc.date.accessioned2021-12-16T15:25:39Z
dc.date.available2021-12-16T15:25:39Z
dc.date.issued2021
dc.identifier.citationGarrido, Victoria; Piñero-Lambea, Carlos; Rodriguez-Arce, Irene [et al.]. Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo. Molecular Systems Biology, 2021, 17, e10145. Disponible en: <https://www.embopress.org/doi/full/10.15252/msb.202010145>. Fecha de acceso: 16 dic. 2021. DOI: 10.15252/msb.202010145ca
dc.identifier.issn1744-4292ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/3033
dc.description.abstractBacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections.en
dc.format.extent20ca
dc.language.isoengca
dc.publisherEMBO Pressca
dc.relation.ispartofMolecular Systems Biologyca
dc.relation.ispartofseries17;
dc.rights2021 - The Authors. Published under the terms of the CC BY4.0 license.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherBacterisca
dc.subject.otherGenomaca
dc.subject.otherStaphylococcus aureusca
dc.subject.otherBacteriases
dc.subject.otherGenomaes
dc.subject.otherStaphylococcus aureuses
dc.subject.otherBacteriaen
dc.subject.otherGenomeen
dc.subject.otherStaphylococcus aureusen
dc.titleEngineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivoen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc57ca
dc.subject.udc578ca
dc.subject.udc616.9ca
dc.identifier.doihttps://dx.doi.org/10.15252/msb.202010145ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

2021 - The Authors. Published under the terms of the CC BY4.0 license.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint